Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC et al. (2025)
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Nat Commun, 16 (1), 7717
DOI 10.1038/s41467-025-63091-0, PubMed 40830141

Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O (2025)
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy
Breast Cancer Res, 27 (1), 143
DOI 10.1186/s13058-025-02092-9, PubMed 40790765

Schmidt N, Kornrumpf K, Ries L, Markus K, Ksionsko N, Mazzeo P, Lohrberg M, Sitte M, Salinas-Riester G, Braun T, Dechow A, Herling M, Ianevski A, Aittokallio T, Chapuy B, Bastians H, Wulf GG, Beißbarth T, Dönitz J, Koch R (2025)
Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas
Blood Adv (in press)
DOI 10.1182/bloodadvances.2024015167, PubMed 40758950